FRONTERA THERAPEUTICS

Frontera is a clinical-stage biotech company dedicated to bringing innovative, high-quality, affordable rAAV gene therapies to patients worldwide.

With early stage and preclinical research center, clinical development, and GMP manufacturing facilities in Boston (USA), Shanghai, and Suzhou (China), we have built a world-class drug discovery and development team. Our work is backed by leading academic and industry experts and supported by renowned venture capital firms.

 

We have developed innovative gene therapies pipeline to address significant unmet medical needs in both large-market and rare diseases in ophthalmology, cardiology and neurology. Several programs have  entered or completed Phase II clinical trials, demonstrating global "Best-in-Class" potential with strong competitive advantages.

 

Our R&D center has established a robust technology platform for AAV capsids and gene expression cassette engineering. Through a comprehensive in vitro and in vivo screening process, we have secured patent-protected AAV vectors that offer precise tissue targeting, more durable gene transduction, and potentially lower immunogenicity.

 

The company has developed a comprehensive Sf9 insect cell-baculovirus expression vector system (Sf9 BEVS) and operates a state-of-the-art AAV GMP manufacturing facility with a fully integrated quality control system. Our robust, scalable production and purification processes - together with a comprehensive analytical assay platform - achieve industry-leading yields while establishing a new benchmark for low empty capsid levels. By significantly reducing the manufacturing cost compared to the commercialized product of the same type, our system and platform enables greater patient access and affordability.

Key Milestone